RLAY — Relay Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1812364 ·
Last close
$17.41
Market Cap
$3.82B
52W High
$21.27
52W Low
$5.85
ADV30
3,417,466
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 350,000 | — | -90,824,000 | -83,707,000 | 967,457,000 | 121,189,000 | 77,448,000 |
| Mar 2026 | 3,000,000 | — | -78,590,000 | -73,291,000 | 699,613,000 | 204,589,000 | 57,430,000 |
| Dec 2025 | 7,000,000 | — | -60,630,000 | -54,890,000 | 621,331,000 | 84,018,000 | 54,271,000 |
| Sep 2025 | 0 | — | -80,391,000 | -74,149,000 | 670,000,000 | 91,564,000 | 62,291,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-212,205,000
Investing CF
$-244,937,000
Financing CF
$463,468,000
CapEx
$-411,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.57
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,171,767,000
Inventory
—
Receivables
—
ST Investments
$789,745,000
EBIT TTM
$-310,435,000
Pretax Income TTM
$-286,037,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,350,000
EBITDA
$-308,224,000
Free Cash Flow
$-119,241,872
Enterprise Value
$3,254,926,592
Total Cash
$910,934,016
Total Debt
$30,658,000
Shares Out
219,141,631
Trailing EPS
$-1.56
Book Value
$4.07
ROE
-36.8%
ROA
-22.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 15,355,000 | -302,738,000 | -276,479,000 | 621,331,000 | 54,271,000 | 567,060,000 | -235,455,000 |
| Dec 2024 | 10,007,000 | -385,674,000 | -337,708,000 | 871,296,000 | 93,504,000 | 777,792,000 | -249,107,000 |
| Dec 2023 | 25,546,000 | -379,422,000 | -341,973,000 | 843,980,000 | 91,977,000 | 752,003,000 | -300,316,000 |
| Dec 2022 | 1,381,000 | -310,952,000 | -290,509,000 | 1,099,771,000 | 149,553,000 | 950,218,000 | -229,490,000 |
TTM Snapshot
Revenues TTM
$10,676,000
NetIncome TTM
$-272,705,000
OpCashFlow TTM
—
Assets (Latest)
$699,613,000
Forward EPS
$-1.64
Max Pain — expiry 2026-12-18
max pain strike: $20.00 · spot: $18.14 · call oi: 7,718 · put oi: 7,348
Expected Move to 2026-12-18:
±$4.28
(23.57%) —
implied range
$13.86 –
$22.41
· ATM straddle on $18.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADPT | Adaptive Biotechnologies Corp | $4.16B | $26.09 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.38B | $72.22 | — |
| CRSP | CRISPR Therapeutics AG | $4.88B | $50.44 | — |
| DNLI | Denali Therapeutics Inc. | $2.98B | $18.67 | — |
| SRRK | Scholar Rock Holding Corp | $5.14B | $42.20 | — |
News headlines (Yahoo Finance, 1h cache)
Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value
2026-10-08 06:12 · Yahoo
Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?
2026-10-08 02:10 · Yahoo
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
2026-09-22 13:30 · Yahoo
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
2026-09-02 17:20 · Yahoo
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
2026-09-01 20:46 · Yahoo
This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion
2026-08-21 19:43 · Yahoo
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year
2026-08-13 15:00 · Yahoo
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
2026-08-06 23:10 · Yahoo
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
2026-08-06 20:05 · Yahoo
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
2026-07-30 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.